Transferrin neuropharmaceutical agent fusion protein (US5672683)

Application Number	Filed	Pub. Date	Title
US1992000999803	1992-11-20
US1992000846830	1992-03-06	1993-01-26	Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US1989000404089	1989-09-07	1992-10-13	Transferrin receptor specific antibody-neuropharmaceutical agent conjugates


	Parent Case:			RELATED APPLICATIONS This Application is a Continuation-in-Part of U.S. Ser. No. 07/999,803 filed Nov. 20, 1992, now abandoned, which is a Divisional of U.S. Ser. No. 07/846,830 filed Mar. 6, 1992 (now U.S. Pat. No. 5,182,107), which is a CIP of PCT/US90/05077, filed Sep. 7, 1990, designating the United States which, in turn, is a Continuation-in-Part of U.S. application Ser. No. 07/404,089 filed Sep. 7, 1989 (now U.S. Pat. No. 5,154,924).
	Designated Country:			AM AP BB BG BR BY CN CZ FI GE HU KE KG KP KR KZ LK LT LV MD MG MN BE CH DK FR GB GR IE IT LI LU MC
	Family:			Show 43 known family members
	First Claim: Show all 11 claims			We claim: 1. A fusion protein comprising transferrin at the carboxyl terminus linked to a neuropharmaceutical agent at the amino terminus, wherein said neuropharmaceutical agent is either nerve growth factor (NGF) or ciliary neurotrophic factor (CNTF).
	Background / Summary:			Show background / summary
	Drawing Descriptions:			Show drawing descriptions
	Description:			Show description
	Forward References:			Show 32 U.S. patent(s) that reference this one

U.S. References:

Go to Result Set: All U.S. references | Forward references (32) | Backward references (23) | Citation Link

Patent	Pub.Date	Inventor	Assignee	Title
US4292425	1981-09	Buckler et al.	Miles Laboratories, Inc.	βGalactosyl-umbelliferone valproic acid conjugates
US4434156	1984-02	Trowbridge	The Salk Institute for Biological Studies	Monoclonal antibodies specific for the human transferrin receptor glycoprotein
US4444744	1984-04	Goldenberg		Tumor localization and therapy with labeled antibodies to cell surface antigens
US4545985	1985-10	Pastan et al.	The United States of America as represented by the Secretary, Dept. of Health and Human Services	Pseudomonas exotoxin conjugate immunotoxins
US4569789	1986-02	Blattler et al.	Dana-Farber Cancer Institute, Inc.	Acid-cleavable compound, use in protein conjugates and drug delivery systems
US4626507	1986-12	Trowbridge et al.	The Salk Institute for Biological Studies	Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein
US4631190	1986-12	Shen et al.		Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4801575	1989-01	Pardridge	The Regents of the University of California	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4816567	1989-03	Cabilly et al.	Genentech, Inc.	Recombinant immunoglobin preparations
US4886780	1989-12	Faulk		Conjugates of apotransferrin proteins with anti-tumor agents
US4892827	1990-01	Pastan et al.	The United States of America as represented by the Department of Health and Human Services	Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4902505	1990-02	Pardridge	Alkermes	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4992255	1991-02	Pardridge		Capillary depletion method for quantifying transcytosis through the blood-brain barrier
US5004697	1991-04	Pardridge	Univ. of CA	Cationized antibodies for delivery through the blood-brain barrier
US5026651	1991-06	Bowman et al.	Board of Regents, The University of Texas System	Methods and compositions for the production of human transferrin
US5028697	1991-07	Johnson et al.	Eli Lilly and Company	Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5087616	1992-02	Meyers et al.	Battelle Memorial Institute	Cytotoxic drug conjugates and their delivery to tumor cells
US5091513	1992-02	Huston et al.	Creative BioMolecules, Inc.	Biosynthetic antibody binding sites
US5108987	1992-04	Faulk		Conjugates of proteins with anti-tumor agents
US5130129	1992-07	Pardridge	The Regents of the University of California	Method for enhancing antibody transport through capillary barriers
US5132405	1992-07	Huston et al.	Creative BioMolecules, Inc.	Biosynthetic antibody binding sites
US5141736	1992-08	Iwasa et al.	Takeda Chemical Industries, Ltd.	Bispecific monoclonal antibody, its production and use
US5169764	1992-12	Shooter et al.	Regeneron Pharmaceuticals, Inc.	Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras

Foreign References:

Publication	Date	IPC Code	Assignee	Title
EP0094844	1983-11	A61K 47/00	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	Drug-carrier conjugates
EP0175560	1986-03	G01N 33/535	E.I. DU PONT DE NEMOURS AND COMPANY	Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody
EP0196056	1986-10	C12N 15/00	CHIRON CORP	Improved expression using fused genes providing for protein product
EP0253202	1988-01	A61K 39/395	ONCOGEN	Novel immunoconjugates and methods for their use in tumor therapy
EP0286441	1988-10	A61K 35/78	ZYMOGENETICS INC	Novel cytotoxic protein
EP0286418	1988-10	A61K 9/50	THE UNITED STATES OF AMERICA represented by The Secretary The United States Department of Commerce	Anti-retroviral agents and delivery systems for the same
EP0305867	1989-03	C01B 3/00	ETHYL CORPORATION	Hydrogen purification process
EP0324625	1989-07	A61K 39/385	Bunge (Australia) Proprietary Limited	Antigen antibody conjugate
EP0327169	1989-08	A61K 47/00	AKZO N.V.	Immunotoxins from barley toxin
EP0328147	1989-08	A61K 47/00	Bristol-Myers Company	Anthracycline immunoconjugates having a novel linker and methods for theirproduction
EP0336383	1989-10	A61K 47/48	TAKEDA CHEMICAL INDUSTRIES, LTD.	Novel recombinant human lymphotoxin
EP0449769	1991-10	A61K 38/00	ROYAL FREE HOSP SCHOOL MED	CD 25 binding molecules
EP0466222	1992-01	C07K 14/415	DOWELANCO	Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
GB1564666	1980-04	A61K 38/00	FUNG KWOK PUI	HETEROCOMPLEXES OF INTERFERON WITH IMMUNOGLOBULIN AND PHARMACEUTICAL COMPOSITIONS THEREOF
WO8601409	1986-03	A61K 39/00	DANA FARBER CANCER INST INC	ACID-CLEAVABLE COMPOUND
WO8807365	1988-10	A61K 9/16	RANNEY, David, F.	BIODADHESION DRUG CARRIERS FOR ENDOTHELIAL AND EPITHELIAL UPTAKE AND LESIONAL LOCALIZATION OF THERAPEUTIC AND DIAGNOSTIC AGENTS
WO9104753	1991-04	A61K 47/48	CETUS CORPORATION	CONJUGATES OF ANTISENSE OLIGONUCLEOTIDES AND THERAPEUTIC USES THEREOF
WO9109965	1991-07	A61K 38/00	THE UNITED STATES OF AMERICA, represented by THE ...	AN IMPROVED TOXIN FOR CONSTRUCTION OF IMMUNOTOXINS
WO9114438	1991-10	A61K 35/14	MORRISON, Sherie, L.	CHIMERIC ANTIBODIES WITH RECEPTOR BINDING LIGANDS IN PLACE OF THEIR CONSTANT REGION
WO9213570	1992-08	A61K 47/48	BIRNSTIEL, Max, L.	NOVEL COMPLEXES CONTAINING NUCLEIC ACID WHICH CAN BE ABSORBED INTO HIGHER EUCARYOTIC CELLS VIA ENDOCYTOSIS
WO9222332	1992-12	A61K 47/48	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	DRUG DELIVERY OF ANTISENSE OLIGONUCLEOTIDES AND PEPTIDES TO TISSUES IN VIVO AND TO CELLS USING AVIDIN-BIOTIN TECHNOLOGY
WO9310819	1993-06	A61K 47/48	ALKERMES, INC.	PROCESS FOR THE PREPARATION OF TRANSFERRIN RECEPTOR SPECIFIC ANTIBODY-NEUROPHARMACEUTICAL OR DIAGNOSTIC AGENT CONJUGATES